{"DataElement":{"publicId":"63589","version":"4","preferredName":"Leukemia Disease Response Type","preferredDefinition":"the clinical assessment to evaluate response of leukemia to treatment following a standard response criteria per protocol using serial evaluations of patient disease from baseline throughout follow-up.","longName":"LEUK_DZ_RESP_TP","context":"CTEP","contextVersion":"2.31","DataElementConcept":{"publicId":"2190138","version":"1","preferredName":"Leukemia Disease Response","preferredDefinition":"information related to leukemia disease response.","longName":"LEUK_DZ_RESP","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2206719","version":"1","preferredName":"Leukemia Diseases and Disorders","preferredDefinition":"A malignant (clonal) hematologic disorder, involving hematopoietic stem cells and characterized by the presence of primitive or atypical myeloid or lymphoid cells in the bone marrow and the blood.  Leukemias are classified as acute or chronic based on the degree of cellular differentiation and the predominant cell type present.  Leukemia is usually associated with anemia, fever, hemorrhagic episodes and splenomegaly.  Common leukemias include acute myeloid leukemia, chronic myelogenous leukemia, acute lymphoblastic or precursor lymphoblastic leukemia, and chronic lymphocytic leukemia.  Treatment is vital to patient survival; untreated, the natural course of acute leukemias is normally measured in weeks or months, while that of chronic leukemias is more often measured in months or years. -- 2004:A definite pathologic process with a characteristic set of signs and symptoms. It may affect the whole body or any of its parts, and its etiology, pathology, and prognosis may be known or unknown.","longName":"C3161:C2991","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Leukemia","conceptCode":"C3161","definition":"A malignant (clonal) hematologic disorder, involving hematopoietic stem cells and characterized by the presence of primitive or atypical myeloid or lymphoid cells in the bone marrow and the blood. Leukemias are classified as acute or chronic based on the degree of cellular differentiation and the predominant cell type present. Leukemia is usually associated with anemia, fever, hemorrhagic episodes, and splenomegaly. Common leukemias include acute myeloid leukemia, chronic myelogenous leukemia, acute lymphoblastic or precursor lymphoblastic leukemia, and chronic lymphocytic leukemia. Treatment is vital to patient survival; untreated, the natural course of acute leukemias is normally measured in weeks or months, while that of chronic leukemias is more often measured in months or years.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Disease or Disorder","conceptCode":"C2991","definition":"Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F37D0429-01B3-6787-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-03-29","endDate":null,"createdBy":"SBR","dateCreated":"2005-03-29","modifiedBy":"ONEDATA","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2177336","version":"1","preferredName":"Response","preferredDefinition":"Response; a bodily process occurring due to the effect of some foregoing stimulus or agent.","longName":"Response","context":"CTEP","contextVersion":"2.31","Concepts":[{"longName":"Response","conceptCode":"C25755","definition":"Any act or phenomena, or behavior, constituting a reply or reaction of a living organism or its part to some foregoing stimulus or agent.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"AE29A78C-528C-3A05-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-10-29","endDate":null,"createdBy":"SBREXT","dateCreated":"2002-10-29","modifiedBy":"SBR","dateModified":"2005-03-29","changeDescription":"Denise Warzel updated Definition by seraching NCI Thesaurus in Admin tool.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008563","version":"1","preferredName":"Therapy Results","preferredDefinition":"the results or effects (does not include CTC Adverse Events) of therapeutic agents or procedures administered to the patient.","longName":"TX_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B6690D31-4081-494A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2003-01-06","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2003-02-11","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E6E12CB1-3713-3865-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-10-20","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-10-20","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2015423","version":"3","preferredName":"Leukemia Disease Response Type","preferredDefinition":"RECIST response criteria for leukemia.","longName":"LEUK_DZ_RESP_TP","context":"CTEP","contextVersion":"2.31","type":"Enumerated","dataType":"CHARACTER","minLength":"2","maxLength":"50","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"CR","valueDescription":"Complete Response","ValueMeaning":{"publicId":"2570187","version":"1","preferredName":"Complete Response","longName":"2570187","preferredDefinition":"The disappearance of all signs of cancer in response to treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Complete Remission","conceptCode":"C4870","definition":"The disappearance of all signs of cancer in response to treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-DF38-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-06-21","endDate":null,"createdBy":"SBR","dateCreated":"2004-06-21","modifiedBy":"KUMMEROA","dateModified":"2023-09-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B30B0B01-3ADD-1194-E034-0003BA12F5E7","beginDate":"2002-07-10","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-30","modifiedBy":"SBREXT","dateModified":"2007-06-22","deletedIndicator":"No"},{"value":"CR","valueDescription":"COMPLETE RESPONSE; DISAPPERANCE OF ALL TARGET LESIONS","ValueMeaning":{"publicId":"2558541","version":"1","preferredName":"COMPLETE RESPONSE; DISAPPERANCE OF ALL TARGET LESIONS","longName":"2558541","preferredDefinition":"COMPLETE RESPONSE; DISAPPERANCE OF ALL TARGET LESIONS","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B1BA-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B30B0B01-3ADF-1194-E034-0003BA12F5E7","beginDate":"2002-02-11","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-30","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Incomplete response/SD","valueDescription":"INCOMPLETE RESPONSE OR STABLE DISESASE","ValueMeaning":{"publicId":"2558961","version":"1","preferredName":"INCOMPLETE RESPONSE OR STABLE DISESASE","longName":"2558961v1.00","preferredDefinition":"Persistence of one or more non-target lesions.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Incomplete Response/Stable Disease","conceptCode":"C150562","definition":"Persistence of one or more non-target lesions.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B35E-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"KUMMEROA","dateModified":"2023-09-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B30B0B01-3AE1-1194-E034-0003BA12F5E7","beginDate":"2002-02-11","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-30","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Insufficient evaluation to determine response status","valueDescription":"INSUFFICIENT EVALUATION","ValueMeaning":{"publicId":"2558974","version":"1","preferredName":"INSUFFICIENT EVALUATION","longName":"2558974v1.00","preferredDefinition":"Not meeting a quantitative or qualitative measure necessary for a requirement._Systematic, objective appraisal of the significance, effectiveness, and impact of activities or condition according to specified objectives and criteria.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Inadequate","conceptCode":"C69177","definition":"Not meeting a quantitative or qualitative measure necessary for a requirement.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Evaluation","conceptCode":"C25214","definition":"Systematic, objective appraisal of the significance, effectiveness, and impact of activities or condition according to specified objectives and criteria.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B36B-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"KUMMEROA","dateModified":"2023-09-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B30B0B01-3AE3-1194-E034-0003BA12F5E7","beginDate":"2002-02-11","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-30","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"PD","valueDescription":"PROGRESSION; AT LEAST A 20% INCREASE IN THE SUM OF LD OF TARGET LESIONS TAKING AS REFERENCES THE SMALLEST SUM LD RECORDED SINCE THE TREATMENT STARTED OR THE APPEARANCE OF ONE OR MORE NEW LESIONS","ValueMeaning":{"publicId":"2559907","version":"1","preferredName":"PROGRESSION; AT LEAST A 20% INCREASE IN THE SUM OF LD OF TARGET LESIONS TAKING AS REFERENCES THE SMALLEST SUM LD RECORDED SINCE THE TREATMENT STARTED OR THE APPEARANCE OF ONE OR MORE NEW LESIONS","longName":"2559907","preferredDefinition":"PROGRESSION; AT LEAST A 20% INCREASE IN THE SUM OF LD OF TARGET LESIONS TAKING AS REFERENCES THE SMALLEST SUM LD RECORDED SINCE THE TREATMENT STARTED OR THE APPEARANCE OF ONE OR MORE NEW LESIONS","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B710-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B30B0B01-3AE5-1194-E034-0003BA12F5E7","beginDate":"2002-02-11","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-30","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"PD","valueDescription":"Progressive Disease","ValueMeaning":{"publicId":"2559908","version":"1","preferredName":"Progressive Disease","longName":"2559908","preferredDefinition":"Cancer that is increasing in scope or severity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Progressive Disease","conceptCode":"C35571","definition":"A clinical, pathologic, and/or molecular finding indicating that the course of a disease is worsening in terms of extent or severity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B711-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"HARTLEYG","dateModified":"2014-10-10","changeDescription":"Manually Curated for OHSU 10262","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B30B0B01-3AE7-1194-E034-0003BA12F5E7","beginDate":"2002-07-10","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-30","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"PR","valueDescription":"Partial Response","ValueMeaning":{"publicId":"2559721","version":"1","preferredName":"Partial Response","longName":"2559721","preferredDefinition":"A decrease in the size of a tumor, or in the extent of cancer in the body, in response to treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Partial Response","conceptCode":"C18212","definition":"A decrease in the size of a tumor, or in the extent of cancer in the body, in response to treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B656-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"SOKKERL","dateModified":"2023-09-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B30B0B01-3AE9-1194-E034-0003BA12F5E7","beginDate":"2002-07-10","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-30","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"PR","valueDescription":"PARTIAL RESPONSE; AT LEAST A 30% DECREASE IN THE SUM OF LD OF TARGET LESIONS TAKING AS REFERENCE THE BASELINE SUM LD","ValueMeaning":{"publicId":"2559722","version":"1","preferredName":"PARTIAL RESPONSE; AT LEAST A 30% DECREASE IN THE SUM OF LD OF TARGET LESIONS TAKING AS REFERENCE THE BASELINE SUM LD","longName":"2559722","preferredDefinition":"PARTIAL RESPONSE; AT LEAST A 30% DECREASE IN THE SUM OF LD OF TARGET LESIONS TAKING AS REFERENCE THE BASELINE SUM LD","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B657-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B30B0B01-3AEB-1194-E034-0003BA12F5E7","beginDate":"2002-02-11","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-30","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"SD","valueDescription":"Stable Disease","ValueMeaning":{"publicId":"2560100","version":"1","preferredName":"Stable Disease","longName":"2560100","preferredDefinition":"Cancer that is neither decreasing nor increasing in extent or severity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stable Disease","conceptCode":"C18213","definition":"A disease that is neither decreasing nor increasing in extent or severity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B7D1-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"KUMMEROA","dateModified":"2022-09-13","changeDescription":"Manually curated for OHSU 10262","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B30B0B01-3AED-1194-E034-0003BA12F5E7","beginDate":"2002-07-10","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-30","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"SD","valueDescription":"STABLE DISEASE; NEITHER SUFFICIENT SHRINKAGE TO QUALIFY FOR PR NOR SUFFICIENT INCREASE TO QUALIFY FOR PD TAKING AS REFERENCES THE SMALLEST SUM LD SINCE THE TREATMENT STARTED","ValueMeaning":{"publicId":"2560103","version":"1","preferredName":"STABLE DISEASE; NEITHER SUFFICIENT SHRINKAGE TO QUALIFY FOR PR NOR SUFFICIENT INCREASE TO QUALIFY FOR PD TAKING AS REFERENCES THE SMALLEST SUM LD SINCE THE TREATMENT STARTED","longName":"2560103","preferredDefinition":"STABLE DISEASE; NEITHER SUFFICIENT SHRINKAGE TO QUALIFY FOR PR NOR SUFFICIENT INCREASE TO QUALIFY FOR PD TAKING AS REFERENCES THE SMALLEST SUM LD SINCE THE TREATMENT STARTED","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B7D4-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B30B0B01-3AEF-1194-E034-0003BA12F5E7","beginDate":"2002-02-11","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-30","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Nodular partial response (nPR)","valueDescription":"Nodular Partial Response","ValueMeaning":{"publicId":"3855514","version":"1","preferredName":"Nodular Partial Response","longName":"3855514","preferredDefinition":"Remission with remaining lymphoid nodules reflecting residual disease.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nodular Partial Response","conceptCode":"C103422","definition":"Remission with remaining lymphoid nodules reflecting residual disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E3F1A8E1-C224-7BE9-E040-BB89AD431625","latestVersionIndicator":"Yes","beginDate":"2013-08-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-08-14","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7359E851-0376-6589-E053-F662850AC0FD","beginDate":"2018-08-14","endDate":null,"createdBy":"MORENOC","dateCreated":"2018-08-14","modifiedBy":"ONEDATA","dateModified":"2018-08-14","deletedIndicator":"No"},{"value":"Refractory Disease","valueDescription":"Refractory Disease","ValueMeaning":{"publicId":"4571271","version":"1","preferredName":"Refractory Disease","longName":"4571271","preferredDefinition":"A disease that resists treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Refractory Disease","conceptCode":"C39752","definition":"A disease that resists treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"06FECA4E-7E2B-9714-E050-BB89AD432ED0","latestVersionIndicator":"Yes","beginDate":"2014-11-03","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-11-03","modifiedBy":"KUMMEROA","dateModified":"2023-03-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6F3BDD90-3D5C-4DE3-E053-F662850A3753","beginDate":"2018-06-22","endDate":null,"createdBy":"MORENOC","dateCreated":"2018-06-22","modifiedBy":"ONEDATA","dateModified":"2018-06-22","deletedIndicator":"No"},{"value":"Relapse","valueDescription":"Relapse","ValueMeaning":{"publicId":"5035791","version":"1","preferredName":"Relapse","longName":"5035791","preferredDefinition":"The return of signs and symptoms of cancer after a period of improvement.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Relapse","conceptCode":"C0699753","definition":"The return of signs and symptoms of cancer after a period of improvement.","evsSource":"UMLS_CUI","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"223EE1E8-286D-61CF-E050-BB89AD436EF1","latestVersionIndicator":"Yes","beginDate":"2015-10-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2015-10-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6F3BDD90-3D66-4DE3-E053-F662850A3753","beginDate":"2018-06-22","endDate":null,"createdBy":"MORENOC","dateCreated":"2018-06-22","modifiedBy":"ONEDATA","dateModified":"2018-06-22","deletedIndicator":"No"},{"value":"Morphologic Complete Remission with Partial Blood Count Recovery (CRh)","valueDescription":"Morphologic Complete Response With Partial Blood Count Recovery","ValueMeaning":{"publicId":"6341375","version":"1","preferredName":"Morphologic Complete Response With Partial Blood Count Recovery","longName":"6341375","preferredDefinition":"The disappearance of all signs of cancer, supported by morphological analysis.: Used to indicate the presence of something or someone.: Being or affecting only a part of something.: A liquid tissue; its major function is to transport oxygen throughout the body. It also supplies the tissues with nutrients, removes waste products, and contains various components of the immune system defending the body against infection. Several hormones also travel in the blood.: To determine the number or amount of something; the result of this activity.: A getting back or regaining.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Morphologic Complete Response","conceptCode":"C123595","definition":"The disappearance of all signs of cancer, supported by morphological analysis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"5"},{"longName":"With","conceptCode":"C62355","definition":"Used to indicate the presence of something or someone.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Partial","conceptCode":"C25378","definition":"Being or affecting only a part of something.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Blood","conceptCode":"C12434","definition":"A liquid tissue; its major function is to transport oxygen throughout the body. It also supplies the tissues with nutrients, removes waste products, and contains various components of the immune system defending the body against infection. Several hormones also travel in the blood.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Count","conceptCode":"C25463","definition":"Determining the number or amount of something.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Recovery","conceptCode":"C70827","definition":"A getting back or regaining.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6F3BDD90-3D78-4DE3-E053-F662850A3753","latestVersionIndicator":"Yes","beginDate":"2018-06-22","endDate":null,"createdBy":"MORENOC","dateCreated":"2018-06-22","modifiedBy":"ONEDATA","dateModified":"2018-06-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6F3BDD90-3D91-4DE3-E053-F662850A3753","beginDate":"2018-06-22","endDate":null,"createdBy":"MORENOC","dateCreated":"2018-06-22","modifiedBy":"ONEDATA","dateModified":"2018-06-22","deletedIndicator":"No"},{"value":"Complete remission (CR)","valueDescription":"Complete Remission","ValueMeaning":{"publicId":"3854972","version":"1","preferredName":"Complete Remission","longName":"3854972","preferredDefinition":"The disappearance of all signs of cancer in response to treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Complete Remission","conceptCode":"C4870","definition":"The disappearance of all signs of cancer in response to treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E3DF4512-86FD-A83E-E040-BB89AD431C6D","latestVersionIndicator":"Yes","beginDate":"2013-08-13","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-08-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":"Manually curated for OHSU 10262","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6F3BDD90-3DA5-4DE3-E053-F662850A3753","beginDate":"2018-06-22","endDate":null,"createdBy":"MORENOC","dateCreated":"2018-06-22","modifiedBy":"ONEDATA","dateModified":"2018-06-22","deletedIndicator":"No"},{"value":"Morphologic Complete Remission with Incomplete Blood Count Recovery (CRi)","valueDescription":"Morphologic Complete Remission with Incomplete Blood Count Recovery ","ValueMeaning":{"publicId":"3854971","version":"1","preferredName":"Morphologic Complete Remission with Incomplete Blood Count Recovery ","longName":"3854971","preferredDefinition":"The disappearance of all cells with morphologic characteristics of cancer, accompanied by incomplete bone marrow recovery, as evidenced by persistent anemia, thrombocytopenia or neutropenia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Morphologic Complete Remission with Incomplete Blood Count Recovery","conceptCode":"C123596","definition":"The disappearance of all cells with morphologic characteristics of cancer, accompanied by incomplete bone marrow recovery, as evidenced by persistent anemia, thrombocytopenia or neutropenia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E3DF4512-86DA-A83E-E040-BB89AD431C6D","latestVersionIndicator":"Yes","beginDate":"2013-08-13","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-08-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6F3BDD90-3DAF-4DE3-E053-F662850A3753","beginDate":"2018-06-22","endDate":null,"createdBy":"MORENOC","dateCreated":"2018-06-22","modifiedBy":"ONEDATA","dateModified":"2018-06-22","deletedIndicator":"No"},{"value":"Partial response except persistent lymphocytosis (PRL)","valueDescription":"Partial Remission Other Than Persistent Lymphocytosis","ValueMeaning":{"publicId":"6349269","version":"1","preferredName":"Partial Remission Other Than Persistent Lymphocytosis","longName":"6349269","preferredDefinition":"A finding indicating that there is a decrease in the size and the extent of tissue involvement by a malignant tumor in a patient.: Distinct from those already mentioned, listed, or considered.: Retained; never-ceasing.: A laboratory test result indicating an abnormal increase in the number of lymphocytes in the peripheral blood, effusions, or bone marrow.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Partial Remission","conceptCode":"C18058","definition":"A finding indicating that there is a decrease in the size and the extent of tissue involvement by a malignant tumor in a patient.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Other Than","conceptCode":"C151896","definition":"Distinct from those already mentioned, listed, or considered.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Persistent","conceptCode":"C43623","definition":"Retained; never-ceasing.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Lymphocytosis","conceptCode":"C34791","definition":"A finding indicating the presence of a non-neoplastic or neoplastic proliferation of lymphocytes in the peripheral blood, effusions, or bone marrow.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"70B9D9FF-0135-187B-E053-F662850A888F","latestVersionIndicator":"Yes","beginDate":"2018-07-11","endDate":null,"createdBy":"MORENOC","dateCreated":"2018-07-11","modifiedBy":"ONEDATA","dateModified":"2018-07-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"70B9D9FF-014E-187B-E053-F662850A888F","beginDate":"2018-07-11","endDate":null,"createdBy":"MORENOC","dateCreated":"2018-07-11","modifiedBy":"ONEDATA","dateModified":"2018-07-11","deletedIndicator":"No"},{"value":"Complete response with incomplete recovery (CRi)","valueDescription":"Complete Remission With Incomplete Recovery","ValueMeaning":{"publicId":"6349270","version":"1","preferredName":"Complete Remission With Incomplete Recovery","longName":"6349270","preferredDefinition":"The disappearance of all signs of cancer in response to treatment.: Used to indicate the presence of something or someone.: Not whole; lacking some necessary part or detail; unfinished.: A healing process and/or an outcome implying relative health.  The term is typically used in the context of direct and indirect effects of sickness or injury.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Complete Remission","conceptCode":"C4870","definition":"The disappearance of all signs of cancer in response to treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"With","conceptCode":"C62355","definition":"Used to indicate the presence of something or someone.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Incomplete","conceptCode":"C49160","definition":"Not whole; lacking some necessary part or detail; unfinished.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Recovery","conceptCode":"C25746","definition":"A healing process and/or an outcome implying relative health.  The term is typically used in the context of direct and indirect effects of sickness or injury.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"70B9D9FF-015D-187B-E053-F662850A888F","latestVersionIndicator":"Yes","beginDate":"2018-07-11","endDate":null,"createdBy":"MORENOC","dateCreated":"2018-07-11","modifiedBy":"ONEDATA","dateModified":"2018-07-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"70B9D9FF-0176-187B-E053-F662850A888F","beginDate":"2018-07-11","endDate":null,"createdBy":"MORENOC","dateCreated":"2018-07-11","modifiedBy":"ONEDATA","dateModified":"2018-07-11","deletedIndicator":"No"},{"value":"Complete clinical response (CCR)","valueDescription":"Clinical Complete Response","ValueMeaning":{"publicId":"5838504","version":"1","preferredName":"Clinical Complete Response","longName":"5838504","preferredDefinition":"The disappearance of all signs of cancer based on physical exam, such as palpation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Clinical Complete Response","conceptCode":"C123574","definition":"The disappearance of all signs of cancer based on physical exam, such as palpation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"506DC049-356A-7059-E053-F662850A6D2C","latestVersionIndicator":"Yes","beginDate":"2017-05-26","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-05-26","modifiedBy":"CLOHNES","dateModified":"2023-11-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"70B9D9FF-018A-187B-E053-F662850A888F","beginDate":"2018-07-11","endDate":null,"createdBy":"MORENOC","dateCreated":"2018-07-11","modifiedBy":"ONEDATA","dateModified":"2018-07-11","deletedIndicator":"No"},{"value":"Relapse/Refractory","valueDescription":"Relapse Refractory","ValueMeaning":{"publicId":"6479357","version":"1","preferredName":"Relapse Refractory","longName":"6479357","preferredDefinition":"The return of signs and symptoms of cancer after a period of improvement.: Not responding to treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Relapse","conceptCode":"C18265","definition":"The return of signs and symptoms of cancer after a period of improvement.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Refractory","conceptCode":"C38014","definition":"Not responding to treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"78062BDA-D22A-533A-E053-F662850A68BB","latestVersionIndicator":"Yes","beginDate":"2018-10-12","endDate":null,"createdBy":"MORENOC","dateCreated":"2018-10-12","modifiedBy":"ONEDATA","dateModified":"2018-10-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"78062BDA-D243-533A-E053-F662850A68BB","beginDate":"2018-10-12","endDate":null,"createdBy":"MORENOC","dateCreated":"2018-10-12","modifiedBy":"ONEDATA","dateModified":"2018-10-12","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008550","version":"1","preferredName":"Disease Response","preferredDefinition":"the response criteria (includes RECIST and others) and associated documentation of disease.","longName":"DZ_RESP","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22C0651-216B-5273-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2177853","version":"1","preferredName":"Type","preferredDefinition":"Type; a subdivision of a particular kind of thing.","longName":"Type","context":"CTEP","contextVersion":"2.31","Concepts":[{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C16D625D-02B6-1907-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2003-07-09","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2003-07-09","modifiedBy":"SBR","dateModified":"2005-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B30B0B01-3ADA-1194-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-30","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-30","modifiedBy":"MORENOC","dateModified":"2018-10-12","changeDescription":"ISO 11179 compliance.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008587","version":"2","longName":"Type of Disease","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2811909","version":"1","longName":"Leukemia","context":"CTEP"}]},{"publicId":"2008589","version":"2","longName":"Type of Category","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2811962","version":"1","longName":"Response","context":"CTEP"}]}],"AlternateNames":[{"name":"Alliance","type":"USED_BY","context":"Alliance"}],"ReferenceDocuments":[{"name":"CRF Text","type":"Alternate Question Text","description":"Response Criteria","url":null,"context":"CTEP"},{"name":"CRF Text","type":"Preferred Question Text","description":"Response Status at This Assessment","url":null,"context":"CTEP"},{"name":"1-COMMENT","type":"COMMENT","description":"Note: Data element based on similar elements created for assessment of solid tumor disease following RECIST criteria.","url":null,"context":"CTEP"},{"name":"Source","type":"DATA_ELEMENT_SOURCE","description":"Reference guideline for Solid Tumor Disease: J National Cancer Institute 92(3):205-216, 2000.","url":null,"context":"CTEP"},{"name":"3-COMMENT","type":"COMMENT","description":"Note: Objective response determined by coordinating center.","url":null,"context":"CTEP"},{"name":"CRF Text2","type":"Alternate Question Text","description":"Response assessment based on physical exam","url":null,"context":"Alliance"},{"name":"CRF Text1","type":"Alternate Question Text","description":"Disease response:","url":null,"context":"Alliance"},{"name":"CRF Text3","type":"Alternate Question Text","description":"Clinical status prior to preparative regimen","url":null,"context":"Alliance"},{"name":"CRF Text4","type":"Alternate Question Text","description":"Clinical status prior to transplant","url":null,"context":"Alliance"}],"origin":"Reference guideline for Solid Tumor Disease: J National Cancer Institute 92(3):205-216, 2000.","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"B9197975-88DC-4F24-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2003-03-17","endDate":null,"createdBy":"PWEST","dateCreated":"2003-03-17","modifiedBy":"MORENOC","dateModified":"2019-03-22","changeDescription":"updated to add reference; definition corrected","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}